MX2013011629A - Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina. - Google Patents
Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina.Info
- Publication number
- MX2013011629A MX2013011629A MX2013011629A MX2013011629A MX2013011629A MX 2013011629 A MX2013011629 A MX 2013011629A MX 2013011629 A MX2013011629 A MX 2013011629A MX 2013011629 A MX2013011629 A MX 2013011629A MX 2013011629 A MX2013011629 A MX 2013011629A
- Authority
- MX
- Mexico
- Prior art keywords
- insulin
- antibodies
- growth factor
- agent consisting
- factor antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1235—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
Abstract
La invención se refiere al uso de un agente seleccionado del grupo que consiste en anticuerpos, porciones de anticuerpo, antagonistas del factor de crecimiento tipo insulina, antagonistas del receptor tipo Toll, y mezclas de los mismos para el tratamiento o la profilaxis de ciertas enfermedades.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102011006809A DE102011006809A1 (de) | 2011-04-05 | 2011-04-05 | Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten |
PCT/EP2012/055485 WO2012136534A2 (de) | 2011-04-05 | 2012-03-28 | Verwendung eines mittels aus antikörpern und/oder insulin-like growth factor-antagonisten |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013011629A true MX2013011629A (es) | 2014-03-27 |
Family
ID=45888234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013011629A MX2013011629A (es) | 2011-04-05 | 2012-03-28 | Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina. |
Country Status (10)
Country | Link |
---|---|
US (2) | US9801938B2 (es) |
EP (1) | EP2694540A2 (es) |
KR (1) | KR20140031892A (es) |
AU (1) | AU2012238872A1 (es) |
BR (1) | BR112013025906A2 (es) |
CA (1) | CA2832373A1 (es) |
DE (1) | DE102011006809A1 (es) |
MX (1) | MX2013011629A (es) |
WO (1) | WO2012136534A2 (es) |
ZA (1) | ZA201307986B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011006781A1 (de) * | 2011-04-05 | 2012-10-11 | Mat-Malta Advanced Technologies Limited | Antikörperprodukt, umfassend n spezifische Antikörper |
DE102011006809A1 (de) | 2011-04-05 | 2012-10-11 | Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg | Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten |
KR20180016335A (ko) | 2015-04-17 | 2018-02-14 | 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 | 항-lps 면역글로불린 치료에 대한 임상 반응의 예측성 생체표지자 |
WO2020147950A1 (en) | 2019-01-16 | 2020-07-23 | Ignova Gmbh | Methods of treating fibromyalgia |
US11319382B1 (en) | 2021-06-28 | 2022-05-03 | King Abdulaziz University | Methods for producing and using IgY antibodies targeting the middle east respiratory syndrome coronavirus spike protein to treat or prevent MERS-CoV infection |
CN117860727A (zh) * | 2022-09-26 | 2024-04-12 | 江苏海洋大学 | 一种用于预防或治疗疼痛的药物组合物 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0225254B1 (en) * | 1985-11-25 | 1994-03-16 | Ghen Corporation | Specific antibody-containing substance from eggs and method of production and use thereof |
DE58904683D1 (de) * | 1988-04-19 | 1993-07-22 | Biotest Pharma Gmbh | Praeparat mit antikoerperaktivitaet und breitem wirkungsspektrum, daraus bestehende oder diese enthaltende mittel und deren verwendung zur behandlung von bakteriell oder toxin-bedingten erkrankungen und zur bekaempfung von protozoen. |
US5332567A (en) | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
JP3195631B2 (ja) * | 1991-02-16 | 2001-08-06 | 太陽化学株式会社 | 特異的鶏卵抗体の製造方法 |
GB9105292D0 (en) | 1991-03-13 | 1991-04-24 | Sandoz Ltd | Improvements in or relating to organic compounds |
AUPN115095A0 (en) * | 1995-02-15 | 1995-03-09 | Butt, Henry Lawrence | Analysis of and compositions and methods for the treatment of disease |
DE19548221C1 (de) * | 1995-12-22 | 1997-05-15 | Biotest Pharma Gmbh | Orale Anwendung von Immunglobulin-Präparationen zur Behandlung und Prophylaxe chronischer Schmerzzustände |
CZ287989B6 (cs) | 1998-03-20 | 2001-03-14 | Medipharm Cz, S. R. O. | Perorální přípravek k prevenci a léčbě infekčních gastroenteritid prasat |
JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
US6346247B1 (en) | 1999-10-28 | 2002-02-12 | Promega Corporation | Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
CA2395840A1 (en) | 1999-12-27 | 2001-07-05 | The University Of Manitoba | Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic escherichia coli and other pathogens |
ES2609016T3 (es) * | 2000-06-16 | 2017-04-18 | Human Genome Sciences, Inc. | Anticuerpos que se unen inmunoespecíficamente a BLyS |
US20030099633A1 (en) | 2001-10-09 | 2003-05-29 | Campbell Joy M. | Methods and compositions for treatment of immune dysfunction disorders |
AU2003901008A0 (en) | 2003-03-04 | 2003-03-20 | Anadis Ltd | Composition for the treatment and prevention of bacterial infections |
US20060034846A1 (en) * | 2003-04-14 | 2006-02-16 | Mirella Ezban | Use of TF antagonists |
KR101233648B1 (ko) | 2004-09-29 | 2013-02-15 | 시즈오카켄 | 유청 단백, 젖 유래의 항체 또는 항체를 포함하는 기능성조성물 또는 식품 |
EP2805971A1 (en) * | 2005-11-28 | 2014-11-26 | ZymoGenetics, Inc. | IL-21 antagonists |
DK2061510T3 (en) * | 2006-08-31 | 2016-09-05 | A C N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust | Treatment and / or prevention of Barrett's esophagus using anti-EphB4 antibody-containing compositions |
US7879894B2 (en) * | 2006-11-28 | 2011-02-01 | Warsaw Orthopedic, Inc. | Use of anti-cytokine agents for treating carpal and tarsal tunnel syndrome |
BRPI0720280A2 (pt) * | 2006-12-11 | 2014-01-28 | Wyeth Corp | Métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13 |
EP1982999A1 (en) * | 2007-04-16 | 2008-10-22 | Friesland Brands B.V. | Milk derived antigen specific antibodies, methods of preparation and uses thereof |
AU2009258063B2 (en) * | 2007-06-21 | 2014-09-25 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
RU2570559C2 (ru) * | 2007-12-17 | 2015-12-10 | Пфайзер Лимитед | Лечение интерстициального цистита |
WO2009092383A2 (en) | 2008-01-22 | 2009-07-30 | Multimerics Aps | Products and methods to prevent infection |
DK2268669T3 (da) * | 2008-03-13 | 2017-11-20 | Immuron Ltd | Bovin kolostrum omfattende antistoffer mod insulin til behandling af stofskifteforstyrrelsessygdomme |
EP3461840A1 (en) | 2009-04-27 | 2019-04-03 | Immuron Limited | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of non alcoholic steatohepatitis |
WO2011036539A1 (en) | 2009-09-23 | 2011-03-31 | Borody Thomas J | Therapy for enteric infections |
EP2605791B1 (en) | 2010-08-17 | 2017-03-08 | Immuron Limited | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder |
US20130273074A1 (en) | 2010-10-04 | 2013-10-17 | Immuron Limited | Methods and Compositions Using Anti-LPS Ligands for the Treatment and Prevention of Inflammatory Disorders |
DE102011006781A1 (de) | 2011-04-05 | 2012-10-11 | Mat-Malta Advanced Technologies Limited | Antikörperprodukt, umfassend n spezifische Antikörper |
DE102011006809A1 (de) | 2011-04-05 | 2012-10-11 | Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg | Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten |
US8926980B2 (en) | 2011-07-11 | 2015-01-06 | Camas Incorporated | Compositions against bacterial toxins |
-
2011
- 2011-04-05 DE DE102011006809A patent/DE102011006809A1/de not_active Withdrawn
-
2012
- 2012-03-28 CA CA2832373A patent/CA2832373A1/en not_active Abandoned
- 2012-03-28 AU AU2012238872A patent/AU2012238872A1/en not_active Abandoned
- 2012-03-28 BR BR112013025906A patent/BR112013025906A2/pt not_active IP Right Cessation
- 2012-03-28 MX MX2013011629A patent/MX2013011629A/es not_active Application Discontinuation
- 2012-03-28 EP EP12710749.8A patent/EP2694540A2/de not_active Ceased
- 2012-03-28 WO PCT/EP2012/055485 patent/WO2012136534A2/de active Application Filing
- 2012-03-28 KR KR1020137029359A patent/KR20140031892A/ko not_active Application Discontinuation
- 2012-03-28 US US14/110,104 patent/US9801938B2/en active Active
-
2013
- 2013-10-24 ZA ZA2013/07986A patent/ZA201307986B/en unknown
-
2017
- 2017-02-15 US US15/433,497 patent/US9913904B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20140112937A1 (en) | 2014-04-24 |
AU2012238872A1 (en) | 2013-10-31 |
US9801938B2 (en) | 2017-10-31 |
WO2012136534A3 (de) | 2012-11-29 |
KR20140031892A (ko) | 2014-03-13 |
US9913904B2 (en) | 2018-03-13 |
EP2694540A2 (de) | 2014-02-12 |
DE102011006809A1 (de) | 2012-10-11 |
BR112013025906A2 (pt) | 2016-09-06 |
US20170252438A1 (en) | 2017-09-07 |
WO2012136534A2 (de) | 2012-10-11 |
ZA201307986B (en) | 2015-09-30 |
CA2832373A1 (en) | 2012-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX356337B (es) | Anticuerpos contra csf-1r humano y sus usos. | |
MX2013009362A (es) | Anticuerpo contra el csf-1r. | |
PH12017500864A1 (en) | Anti-notch1 antibodies | |
WO2013119716A8 (en) | Compositions and methods for using csf1r inhibitors | |
PH12014502010A1 (en) | Bispecific antibodies against human tweak and human il17 and uses thereof | |
MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
SG194701A1 (en) | Anti-cd40 antibodies and methods of use | |
MA34091B1 (fr) | Anticorps anti-cd40 | |
MX342240B (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
EP3702372A3 (en) | Anti-cd40 human antibodies | |
MX2014004022A (es) | Anticuerpos anti-htra1 y metodos de uso. | |
MX354988B (es) | Formulaciones de anticuerpo y metodos. | |
SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
MX346500B (es) | Metodos y composiciones para inmunoterapia para enfermedad neural. | |
MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
MX2013009151A (es) | Inmunoterapia mejorada. | |
MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
MX360774B (es) | Antagonistas de progesterona. | |
EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 | |
MX2014000142A (es) | Uso de anticuerpos agonistas anti-cd83 para tratar enfermedades autoinmunes. | |
MX2013011629A (es) | Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina. | |
MX2013001267A (es) | ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD. | |
EP3492101A3 (en) | Agents for influenza neutralization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |